Elevated serum progastrin‐releasing peptide (31–98) in metastatic and androgen‐independent prostate cancer patients

BACKGROUND Increases in neuroendocrine phenotype and secretory products are closely correlated with tumor progression and androgen independence in prostate cancer. In this study, we explored this correlation using serum progastrin‐releasing peptide (ProGRP), a carboxy‐terminal region common to three...

Full description

Saved in:
Bibliographic Details
Published in:The Prostate 2002-05, Vol.51 (2), p.84-97
Main Authors: Yashi, Masahiro, Muraishi, Osamu, Kobayashi, Yutaka, Tokue, Akihiko, Nanjo, Hiroshi
Format: Article
Language:English
Subjects:
Adult
Aged
Androgens - pharmacology
androgen‐independent
Biomarkers, Tumor - analysis
Disease Progression
Enzyme-Linked Immunosorbent Assay
Gastrin-Releasing Peptide - blood
Gastrins - blood
gastrin‐releasing peptide
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Longitudinal Studies
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
neuroendocrine differentiation
Peptide Fragments - blood
Peptides - blood
Phenotype
progastrin‐releasing peptide (31–98)
prostate cancer
Prostate-Specific Antigen - blood
Prostatic Neoplasms - pathology
Protein Precursors - blood
Recombinant Proteins - blood
Up-Regulation
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND Increases in neuroendocrine phenotype and secretory products are closely correlated with tumor progression and androgen independence in prostate cancer. In this study, we explored this correlation using serum progastrin‐releasing peptide (ProGRP), a carboxy‐terminal region common to three subtypes of precursors for gastrin‐releasing peptide (GRP), which is released from the neuroendocrine phenotype to act as a growth factor. METHODS In 60 patients with benign prostatic hyperplasia (BPH) and 200 with prostate cancer, serum ProGRP levels were determined with an enzyme‐linked immunosorbent assay (ELISA) kit and evaluated in relation to clinical stage, hormonal treatment, and prostate‐specific antigen (PSA) values. Fourteen randomly selected patients were entered in the follow‐up study. Additionally, expression of ProGRP as determined by immunohistochemical analysis was compared to that of chromogranin‐A (CgA) in tissue samples from several subjects. RESULTS We found a positive correlation between PSA and ProGRP in patients with untreated prostate cancer; no correlation was found in the treated groups. The increases in the ProGRP value and in the percentage of patients with higher than normal values were significant (P 
ISSN:0270-4137
1097-0045
DOI:10.1002/pros.10063